alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 401–425 of 909 studies published 2016 (page 17 of 37) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Identification of Physician-Diagnosed Alzheimer's Disease and Related Dementias in Population-Based Administrative Data: A Validation Study Using Family Physicians' Electronic Medical Records

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of Alzheimer's disease : JAD 2016-08-01

Algorithms developed from health administrative data are sensitive and specific for identifying older adults with AD-RD. 1 key finding →

Participants: 3,404 Evidence: low

Full summary, score breakdown and related studies → Original source

Tract-specific white matter hyperintensities disrupt neural network function in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2016-07-16

WMH volume within the inferior fronto-occipital fasciculus (IFOF) was the highest among all tract ROIs and associated with reduced FC in IFOF-connected DMN areas, independently of global AV-45 PET. 3 key findings →

Participants: 78 Evidence: low

Full summary, score breakdown and related studies → Original source

Appetite and Weight Loss Symptoms in Late-Life Depression Predict Dementia Outcomes

✓ Peer-reviewed alzhub usefulness score 50 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2016-06-06

Higher scores on the appetite and weight loss symptom factor were associated with an increased hazard of both AD and non-AD dementia. 5 key findings →

Participants: 290 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study

✓ Peer-reviewed alzhub usefulness score 49 out of 100. JAMA neurology 2016-12-01

Diagnostic change occurred in 46 patients (79%) having both a previous diagnosis of AD and an amyloid-negative scan (P Conclusions and relevance Amyloid PET in addition to routine assessment in patients with cognitive impairment has a significant effect on diagnosis, diagnostic confidence, and drug treatment. 4 key findings →

Participants: 228 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Alzheimer's & dementia (New York, N. Y.) 2016-01-01

These results suggest that stakeholders in AD prevention research generally wish to know biological test information about their risk for developing AD to assist in making life plans. 5 key findings →

Participants: 207 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Updating the Evidence for Physical Activity: Summative Reviews of the Epidemiological Evidence, Prevalence, and Interventions to Promote "Active Aging"

✓ Peer-reviewed alzhub usefulness score 49 out of 100. The Gerontologist 2016-04-01

Purpose of the study There is a global imperative to increase awareness of the emerging evidence on physical activity (PA) among older adults. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dementia in the acute hospital: the prevalence and clinical outcomes of acutely unwell patients with dementia

✓ Peer-reviewed alzhub usefulness score 49 out of 100. QJM : monthly journal of the Association of Physicians 2016-08-02

A diagnosis of dementia confers an increased risk of either death or further admission within the following 12 months, highlighting the need for better cognitive screening in the acute setting, as well as targeted intervention such as comprehensive geriatric assessment. 3 key findings →

Participants: 190 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The Ontario Neurodegenerative Disease Research Initiative (ONDRI)

✓ Peer-reviewed alzhub usefulness score 49 out of 100. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2016-12-22

Because individuals develop dementia as a manifestation of neurodegenerative or neurovascular disorder, there is a need to develop reliable approaches to their identification. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of neurochemistry 2016-06-15

The multiple roles played by RNA binding proteins in neurodegeneration have become apparent following the discovery of TAR DNA binding protein 43 kDa (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS) involvement in amyotrophic lateral sclerosis and frontotemporal lobar dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Disrupted Network Topology in Patients with Stable and Progressive Mild Cognitive Impairment and Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Cerebral cortex (New York, N.Y. : 1991) 2016-05-13

Recent findings suggest that Alzheimer's disease (AD) is a disconnection syndrome characterized by abnormalities in large-scale networks. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Targeting innate immunity for neurodegenerative disorders of the central nervous system

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of neurochemistry 2016-09-01

Neuroinflammation is critically involved in numerous neurodegenerative diseases, and key signaling steps of innate immune activation hence represent promising therapeutic targets. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurobiology of aging 2016-03-03

Two recent studies have identified that a rare coding variant (p.R47H) in exon 2 of triggering receptor expressed on myeloid cells 2 (TREM2) gene is associated with Alzheimer's disease (AD) susceptibility in Caucasians. 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Normative Data for the Montreal Cognitive Assessment in Middle-Aged and Elderly Quebec-French People

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists 2016-11-01

Given that aging is associated with higher risk of cognitive decline and dementia, improving early detection of cognitive impairment has become a research and clinical priority. 4 key findings →

Participants: 200 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of Alzheimer's disease : JAD 2016-01-01

Neuropsychiatric symptoms, also known as behavioral and psychological symptoms of dementia (BPSD), affect the majority of patients with dementia, and result in a greater cognitive and functional impairment. 4 key findings →

Participants: 657 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Predicting Regional Pattern of Longitudinal β-Amyloid Accumulation by Baseline PET

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016-10-06

Pseudotemporal measurements from baseline PET data explained 87% ( P Pseudotemporal analysis of baseline PET images is capable of predicting the regional pattern of longitudinal Aβ accumulation in AD at a group level. 3 key findings →

Design: longitudinal study Participants: 58 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Workplace violence in different settings and among various health professionals in an Italian general hospital: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Psychology research and behavior management 2016-09-23

This study suggests that violence is a significant phenomenon and that all health workers, especially nurses, are at risk of suffering aggressive assaults. 4 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Cellular and molecular neurobiology 2016-03-01

The World Health Organization reports that 47.5 million people are affected by dementia worldwide. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Oral health status and need for oral care of care-dependent indwelling elderly: from admission to death

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Clinical oral investigations 2016-11-28

When compared to edentulous elderly patients, patients with remaining teeth were younger at admittance, were more often non-cooperative, and had a poorer oral health and higher need for dental care. 5 key findings →

Participants: 725 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed